Kikuo Yasui

COO, Director

Therapeutic Areas

Drug	Indication	Phase
HS-001	Systolic Heart Failure (HFrEF) including Dilated Cardiomyopathy (DCM), Old Myocardial Infarction (OMI), Dilated-phase Hypertrophic Cardiomyopathy (D-HCM)	Phase 1